The authors propose including TP53‐mutated MPN‐BP/AP and multi‐hit MF‐CP in the broader category of “myeloid neoplasms with mutated TP53.” [8, 9] This proposal aligns with established criteria for TP53‐mutated MDS and AML, where multi‐hit status confers distinct prognostic and biological significance. The gene discussed is TP53; the disease is myeloproliferative disorder.